

05-26-00

Box
SEQ

A

Please type a plus sign (+) inside this box → Approved for use through 09/30/2000. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. 4409US

First Inventor or Application Identifier Tamara Maes et al.

Title See 1 in Addendum

Express Mail Label No. EL638948436US

PTO
5327867**APPLICATION ELEMENTS**

See MPEP chapter 600 concerning utility patent application contents.

1. * Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original, and a duplicate for fee processing)
2. Specification [Total Pages 30]
(preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
3. Drawing(s) (35 U.S.C. 113) [Total Sheets 6]
4. Oath or Declaration [Total Pages]
 - a. Newly executed (original or copy)
 - b. Copy from a prior application (37 C.F.R. § 1.63(d))
(for continuation/divisional with Box 17 completed)
[Note Box 5 below]
 - i. DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).
5. Incorporation By Reference (useable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered to be part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

6. Microfiche Computer Program (Appendix)
7. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
 - a. Computer Readable Copy
 - b. Paper Copy (identical to computer copy)
 - c. Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. Assignment Papers (cover sheet & document(s))
9. 37 C.F.R. § 3.73(b) Statement (when there is an assignee) Power of Attorney
10. English Translation Document (if applicable)
11. Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations
12. Preliminary Amendment
13. Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
14. * Small Entity Statement(s) Statement filed in prior application, (PTO/SB/09-12) Status still proper and desired
15. Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. Other:

* A new statement is required to be entitled to pay small entity fees, except where one has been filed in a prior application and is being relied upon.

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

 Continuation Divisional Continuation-in-part (CIP) of prior application No: PCT/EP98/07551

Prior application information: Examiner _____ Group / Art Unit: _____

18. CORRESPONDENCE ADDRESS

Customer Number or Bar Code Label
(Insert Customer No. or Attach bar code label here) or Correspondence address below

Name	Allen C. Turner			
	Trask Britt			
Address	P.O. Box 2550			
City	Salt Lake City	State	Utah	Zip Code
Country	U.S.A.	Telephone	(801) 532-1922	Fax (801) 531-9168

Name (Print/Type)	Allen C. Turner	Registration No. (Attorney/Agent)	33,041
Signature	Date 05/24/00		

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Addendum

1. METHOD OF PARALLEL SCREENING FOR INSERTION MUTANTS AND A KIT TO PERFORM THIS METHOD

MAY 10 '00 (WED) 15:56

Attorney Docket No. 4409US

Applicant or Patentee: Tamara Maes; Tom Gerats

Filed:

Serial No.:

For: METHOD OF PARALLEL SCREENING FOR INSERTION MUTANTS AND A KIT TO PERFORM THIS METHOD

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS (37 C.F.R. §§ 1.9(d) and 1.27 (c)) - SMALL BUSINESS CONCERN

I hereby declare that I am

- the owner of the small business concern identified below;
- an official of the small business concern empowered to act on behalf of the concern identified below;

NAME OF CONCERN: Vlaams Interuniversitair Instituut voor Biotechnologie vzw

ADDRESS OF CONCERN: Blijvisschestraat 120, B-9052 Zwijnaarde, Belgium

I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 C.F.R. § 121.3-18, and reproduced in 37 C.F.R. § 1.9(d), for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled "METHOD OF PARALLEL SCREENING FOR INSERTION MUTANTS AND A KIT TO PERFORM THIS METHOD" by inventor(s) Tamara Maes; Tom Gerats described in

- the specification filed herewith;
- application serial no. _____, filed _____;
- patent no. _____, issued _____.

If the rights held by the above-identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 C.F.R. § 1.9(e). If this person made the invention or by any concern which would not qualify as a small business concern under 37 C.F.R. § 1.9(d) or a nonprofit organization under 37 C.F.R. § 1.9(e).

*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention according to their status as small entities. (37 C.F.R. § 1.27)

NAME: _____
ADDRESS: _____

 Individual Small Business Concern Nonprofit Organization

NAME: _____
ADDRESS: _____

 Individual Small Business Concern Nonprofit Organization


I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to filing, or at the time of filing, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate (37 C.F.R. § 1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING: Rudy Dekuyser

TITLE OF PERSON OTHER THAN OWNER: Vice-General Director

ADDRESS OF PERSON SIGNING: Blijvisschestraat 120, B-9052 Zwijnaarde, Belgium

SIGNATURE: 

DATE: 14/05/00

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Maes et al.

Serial No.: To be assigned

Filed: May 25, 2000

For: METHOD OF PARALLEL
SCREENING FOR INSERTION MUTANTS
AND A KIT TO PERFORM THIS METHOD

Examiner: To be assigned

Group Art Unit: To be assigned

Attorney Docket No.: 4409US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EL638948436US

Date of Deposit with USPS: May 24, 2000

Person making Deposit: Jared Turner

Preliminary Amendment

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Before examination of the application and calculation of the filing fees, please amend the referenced application as follows:

IN THE CLAIMS:

1. (Amended) [Method] A method of [simultaneous] simultaneously screening for one or more gene insertion mutants in a population of any organism or cell line derived thereof, [by], said method comprising:

- [a)] preparing an insertion element mutant library comprising a plurality of nucleic acid insertion elements and originating from a defined population of an organism [or cell line] wherein said [insertion(s)] gene insertion mutants [have] are to be detected[,];
- [b)] amplifying [the] insertion element flanking sequences from said insertion element mutant library[,]; and [c1)] either
 - fixing [the] a set of [thus obtained] nucleic acid amplification products representing said insertion element flanking sequences derived from said insertion element mutant library to a solid support as target for hybridization, or
- [c2)] producing a set of labelled amplification products representing said insertion element flanking sequences derived from said insertion element mutant library to use as probe to hybridize to a solid support to which one or more nucleic acids have been fixed as target(s) for hybridisation.

2. (Amended) [Method] The method according to claim 1 wherein the [thus obtained] set of nucleic acid amplification products [in step b)] representing said insertion element flanking sequences are obtained by iPCR using at least one primer or a set of primers based on [the] a sequence of [the] at least one insertion element.

3. (Amended) [Method] The method according to claim 2 wherein the iPCR [is performed by] comprises:

- [a)] digesting [the] nucleic acid sequences of said insertion element mutant library with [a] at least one restriction enzyme [which optionally recognizes motifs of four nucleotides in the genomic DNA, or with a combination of restriction enzymes] resulting in a collection of amplifyable genomic fragments[,];
- [b)] [self ligation of the] ligating at least one amplifyable genomic [fragments thus obtained]

fragment by self ligation; and either

- c1) [amplification of insertion element flanking sequences]amplifying said at least one amplifyable genomic fragment using a set of internal primers or
- [c2) amplification of]amplifying insertion element flanking sequences using a [(set of)]a primer or set of primers based on the terminal part of the insertion element.

4. (Amended) [Method]The method according to claim 3 wherein the insertion element flanking sequences are amplified by said set of internal primers, and the amplification products [of step c1] are re-amplified using at least one primer or a set of two nested primers based on [the]a sequence of the insertion element.

5. (Amended) [Method]The method according to claim 1 wherein [the amplification products in step b) are obtained by]amplifying insertion element flanking sequences from said insertion element mutant library comprises amplifying said insertion element flanking sequences using transposon display amplification.

6. (Amended) The method [Method] according to claim 5 wherein said transposon display amplification [is performed by]comprises:

[a)] generating at least one restriction fragment corresponding to each of said plurality of nucleic acid insertion elements by digesting [the]a plurality of nucleic acid sequences [of] included in said insertion element mutant library [with]using a first restriction enzyme that recognizes six conserved nucleotides [in the insertion element] and [with] a second restriction enzyme that recognizes a motif of four nucleotides [in the genome generating at least one restriction fragment per insertion containing at least the hexacutter site, a part of the insertion element, and part of the insertion element flanking sequence], said at least one restriction fragment including at least a tetracutter site, a hexacutter site, a part of an insertion element of said plurality of insertion elements, and at least part of an insertion element flanking sequence corresponding to said insertion element;

[b) ligation of]ligating a biotinylated adaptor to the hexacutter [sites and a ligation of]site of each of said at least one restriction fragment as well as a second adaptor to the tetracutter

[sites]site of said at least one restriction fragment [the restriction fragments generated in a,];
[c) selection of]selecting biotinylated restriction fragments using magnetic streptavidin beads[,];
[d) amplification of]amplifying insertion element flanking sequences using a primer based on [the]a sequence of the biotinylated adaptor and on the insertion element sequence and a primer complementary to the second adaptor[,]; and
[e) re-amplification of]re-amplifying said insertion element flanking sequences using a nested primer based on [the]an insertion element and a primer complementary to the second adaptor.

7. (Amended) [Method]The method according to [any of the preceeding claims]claim 1 wherein the solid support is a filter, micro-array, or chip containing nucleic acid sequences.

8. (Amended) [Method]The method according to [any of the preceeding claims] claim 6 wherein the nucleic acid sequences [is] are selected from a group consisting of genomic DNA [or] and cDNA.

9. (Amended) [Method]The method according to [any of the preceeding claims]claim 1 wherein preparing the insertion element mutant library comprises [of] preparing an insertion element mutant library including 30 DNA samples from 100 plants each.

10. (Amended) [Method]The method according to claim 9 wherein preparing the insertion element mutant library including 30 DNA samples from 100 plants each comprises preparing an insertion element mutant library [is] built in a 3D array of 10 Block, 10 Row and 10 Column pool each containing DNA of 100 plants characterised by the three coordinates B, R, C.

11. (Amended) [Method]The method according to [any of the claims 1-4] claim 3 wherein digesting nucleic acid sequences of said insertion element mutant library with at least one restriction enzyme comprises digesting nucleic acid sequences using BfaI [is used] as a restriction enzyme.

12. (Amended) [Method]The method according to [the claims] claim 5 [or 6] wherein amplifying said insertion element flanking sequences using transposon display amplification

comprises using a restriction enzyme selected from a group consisting of MseI and[/or] MunI [are used as restriction enzyme].

13. (Amended) [Kit]A kit for performing [any of the methods]the method of claim [1-12]1 comprising [at least] DNA samples of an insertion element mutant library [and optionally a set of restriction enzymes and/or primers].

14. (Amended) [Kit for performing any of the methods of claim 1-12]The kit of claim 13 further comprising [at least] a set of amplified insertion element flanking sequences.

15. (Amended) [Kit according to]The kit of claim 14 wherein the set of amplified insertion element flanking sequences have been fixed on a solid support, such as a filter, micro-array, or microchip, containing nucleic acid sequences.

16. (Amended) [Kit according to claims 14 or 15]The kit of claim 14 wherein the set of amplified insertion flanking sequences is [either] present in a state selected from a group consisting of a soluble [form or]state and a dried [form]state.

17. (Amended) [Kit according to]The kit of claim 16 wherein the set of amplified insertion element flanking sequences are labelled with [for instance] fluorescein.

Please add the following new claims:

18. A method for simultaneously screening one or more gene insertion mutants in a cell line comprising:

preparing an insertion element mutant library comprising a plurality of nucleic acid insertion elements and originating from a cell line wherein said gene insertion mutants are to be detected;

amplifying insertion element flanking sequences from said insertion element mutant library; and fixing a set of nucleic acid amplification products representing said insertion element flanking

sequences derived from said insertion element mutant library to a solid support as target for hybridization.

19. A method for simultaneous screening for one or more gene insertion mutants in a population of any organism comprising:

preparing an insertion element mutant library comprising a plurality of nucleic acid insertion elements and originating from a defined population of an organism wherein said gene insertion mutants are to be detected;

amplifying insertion element flanking sequences from said insertion element mutant library; and producing a set of labeled amplification products representing said insertion element flanking sequences derived from said insertion element mutant library to use as probes to hybridize to a solid support to which one or more nucleic acids have been fixed as target(s) for hybridisation.

20. The method according to claim 2 wherein said iPCR comprises:

digesting nucleic acid sequences of said insertion element mutant library with at least one restriction enzyme which optionally recognizes motifs of four nucleotides in genomic DNA, resulting in a collection of amplifiable genomic fragments;

ligating at least one amplifiable genomic fragment by self ligation; and

amplifying said at least one amplifiable genomic fragment using primers based on a terminal part of an insertion element.

Remarks

The application is to be amended as previously set forth. The changes are generally made to more appropriately claim the invention in view of United States practice. It is respectfully submitted that no new matter has been added.

Conclusion

In the event questions remain after consideration of these amendments, the Office is kindly requested to contact applicant's attorney at the number given below.

All
Respectfully submitted,
Allen C. Turner

Allen C. Turner
Registration No. 33,041
Attorney for Applicant
TRASK BRITT
P. O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: (801) 532-1922

Date: May 24, 2000

N:\2676\4409\Prelim Amendment.wpd

PATENT
Attorney Docket 4409US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EL638948436US

Date of Deposit with USPS: May 24, 2000

Person making Deposit: Jared Turner

APPLICATION FOR LETTERS PATENT

for

**METHOD OF PARALLEL SCREENING FOR INSERTION MUTANTS AND A KIT TO
PERFORM THIS METHOD**

Inventors:

Tamara Maes
Tom Gerats

Attorney:

Allen C. Turner

Registration No. 33,041

Samuel E. Webb

Registration No. 44,394

TRASK BRITT

P.O. Box 2550

Salt Lake City, Utah 84110

(801) 532-1922

METHOD OF PARALLEL SCREENING FOR INSERTION MUTANTS AND A KIT TO PERFORM THIS METHOD

5 Related Applications: This application is a continuation under 35 U.S.C. §§ 120 and 365(c) of pending application PCT/EP98/07551 filed on November 23, 1998 designating the United States of America, which itself claims priority from European Patent Application EP 97203680.0, filed on November 25, 1997.

10 Field of the invention: The current invention relates to a method of parallel and, as a consequence thereof, simultaneous screening for one or more gene insertion mutants in a population of any organism.

15 Background of the invention: Gene disruption is a powerful tool to assign biological functions to the proteins that are encoded by, for example, the numerous uncharacterised open reading frames ("ORFs") resulting from genome projects or expressed sequence tags ("EST") databases. To characterise the biological function of these ORFs efficiently, three problems must be addressed: (i) how to obtain a saturated population of mutants; (ii) how to efficiently identify the genes that have been mutated in the different individuals or, vice versa, how to find individuals mutated in a specific gene; and (iii) how to analyse their phenotypes.

20 Several strategies have been reported to disrupt specific genes or to simplify the identification of disrupted ORFs. In *Saccharomyces cerevisiae*, tagged mutants have been generated *en masse* by using random transposition of the endogenous Tyl element (Smith *et al.*, 1995). Alternatively, a yeast library in *E. coli* was mutagenised with a Tn3 element (carrying lacZ for the monitoring of expression) followed by homologous recombination of the mutated yeast sequences into the yeast genome (Burns *et al.*, 1994). Shoemaker *et al.* (1996) described an approach to perform a quantitative phenotypic assay of yeast deletion mutants, consisting of three steps: (i) replacement of each of the ~ 6000 ORFs of *S. cerevisiae* with a unique 20 bp tag and a kanamycin marker by homologous recombination; (ii) pooling of the deletion mutants and competitive growth under different selection conditions; (iii) amplification of the tags of the surviving strain and identification of their corresponding genes by hybridization of the isolated tags to a micro array displaying oligonucleotides complementary to the tags for all the yeast genes.

For other organisms, it is not yet possible or too laborious to obtain mutants through homologous recombination. Instead, large populations of individuals carrying random transposon insertions have been generated for *Drosophila melanogaster* (Ballinger and Benzer, 1989, Kaiser and Goodwin, 1990), *Caenorhabditis elegans* (Zwaal *et al.*, 1993),
5 *Petunia hybrida* (Koes *et al.*, 1995) and *Zea mays* (Das and Martienssen, 1995). For *Arabidopsis thaliana*, large populations of T-DNA insertion mutants have been obtained through *Agrobacterium* mediated transformation (Bechtold *et al.*, 1993, Mc Kinney *et al.*, 1995, Mollier *et al.*, 1995). A polymerase chain reaction (“PCR”)-based approach is used to screen these populations for individuals harboring insertions in genes of interest. By
10 combining a gene-specific and an insertion-specific primer in the PCR screen, specific products are amplified only when the transposable element has inserted in that gene (Ballinger and Benzer, 1990, Kaiser and Goodwin, 1990). These populations are commonly organized in pools in a pyramidal or 3D fashion, to allow fast screening and easy identification of the individuals carrying a mutant allele.

15 Using such an approach, the PCR screen has to be repeated for each individual ORF, or at the most, a limited set of gene-specific primers can be combined in the same screen (Mc Kinney *et al.*, 1995). This is a time consuming process and is extremely laborious to carry out.

Summary of the Invention

20 The method according to the invention offers an attractive alternative to the existing strategy used to screen large populations for insertion mutants. The rationale of the previously described PCR based screening for insertion mutants is that whenever an insertion element has inserted in a gene, a product can be amplified in a PCR reaction using a gene- and an insertion-specific primer (Ballinger and Benzer, 1989; Kaiser and Goodwin,
25 1990).

The technique according to the invention reproducibly amplifies *all* the transposon flanking sequences in a pool of individuals, and subsequently identifies insertions by hybridization with a gene-specific probe. By eliminating the use of the gene-specific primer, it becomes possible to perform a serial screening for insertions in a large set of genes using

a single set of PCR reactions. Alternatively, the flanking sequence pools can be used as probes to screen target genes.

This approach was tested using nested iPCR as a means to amplify the transposon *dTph1*-flanking sequences from the DNA pools of a 3D library of 1000 W137 *Petunia* individuals. To amplify *dTph1*-flanking sequences a tetracutter was used that does not cut within the element, the obtained DNA fragments were circularized, *dTph1* flanking sequences were amplified by iPCR using a set of internal primers, and a single primer based on the TIR for nested reamplification. The results indicate that a *dTph1* insertion in a specific gene of a specific plant can be detected against a background of about hundred wild type individuals, both in the serial and in the parallel screening method (see below). The variation in the signals produced for the positive control insertion in *PhAp2A* however indicate that the protocol had to be optimized to ensure that the *dTph1* flanking sequences of *all* the pool samples representing the population are sufficiently well amplified. The efficiency of the tagging system will influence the optimal size of the population to be screened. If n insertions per 1000 plants are found for a specific cDNA clone, $3n$ signals will arise. Direct identification of the candidate plant is only possible if n equals one. Somatic insertions into a gene will interfere and may lead to background hybridization. Stable insertion systems (for example T-DNA insertions) or systems with a controllable or low somatic insertion frequency will not suffer this problem.

The choice of the targets may also influence the efficiency of recovery of phenotypic mutants. If only cDNA targets are used, the percentage of intron and promoter amplified fragments that are recovered should statistically go down, and more knock-out mutants may be recovered, especially if the transposable element is small, harbors no transcription termination signals, and is unlikely to interfere with the gene function when it has inserted in an intron, like *dTph1* in *Petunia*.

The presented technique can be applied to the respective insertion mutagenesis system used for any organism. When the tetracutter recognizes a site within the insertion element, as it will in most cases, a set of two insertion specific primers must be used to amplify the flanking sequences. Instead of iPCR, the transposon flanking sequences can also be obtained by adaptor mediated PCR, as described by Van Den Broeck *et al.*, (1998) or by

vectorette PCR (Riley *et al.*, 1990). The filter based screening, described here to illustrate the potential of the technique, could readily be extended to the microarray technology. In theory, microarrays can be produced displaying up to and over 20,000 targets, and hybridization of fluorescently labeled flanking sequences with those targets can be detected

5 by means of confocal microscopy (Schena *et al.*, 1995). When (micro)arrays, orderly representing the whole genome of an organism are available, the method could be used to quickly catalogue the individual insertions and simultaneously assess the randomness of the insertions in a given population. Micro-arrays containing cDNA targets of an organism can also be used to screen for tagged genes in a closely related organism that is not in itself the

10 subject of major sequencing efforts, if the stringency conditions used in the hybridization reactions are adapted. Such catalogues could also be helpful in identifying genes in map-based cloning strategies. After fine mapping of an interesting mutation, seeds of all the different insertion mutants in the region of interest could be retrieved from the insertion library. Mutant phenotypes in the progenies of the primary insertion mutants could then be

15 compared to that of the originally mapped mutant. When the same or a comparable phenotype arises in such a family, the gene of interest has probably been tagged and thus been identified. Catalogues of insertion mutants can also be generated by isolation and sequencing all the insertion flanking sites found in a population. Using an efficient gene-and enhancer-trap transposon mutagenesis system, based on the maize elements Ac/Ds and the GUS reporter gene, a population of more than 10,000 single copy insertions mutants in *Arabidopsis* has been generated and a few hundred of these insertion alleles have been sequenced. The *dTph1* element in *Petunia* has a high copy number (150-200) in the line used for tagging. Every W137 individual harbors ten to twenty new germline insertions.

20 Analysis of the new insertion sites would require cloning of the individual *dTph1* flanking sequences and selection of the 10% of clones that represent novel insertions. For high copy number tagging systems like *dTph1* in *Petunia*, *Mu* in maize, and *Tc1* in *C. elegans*, the sequencing approach therefore seems too laborious.

25

The current screening system according to the invention offers the opportunity to screen for insertion mutants in large populations of individuals. When used at its full

potential, the efficiency of screening will be increased several orders of magnitude over that of the existing PCR based screening method.

So the first aspect of the current invention is a method of simultaneously screening for one or more gene insertion mutants in a population of any organism by:

- 5 a) preparing an insertion element mutant library originating from a defined population of an organism or cell line wherein said insertion(s) have to be detected;
- b) amplifying the insertion element flanking sequences from said insertion element mutant library; and
- 10 c1) either fixing the set of thus obtained nucleic acid amplification products representing said insertion element flanking sequences derived from said insertion element mutant library to a solid support as target for hybridization; or
- c2) producing a set of labeled amplification products representing said insertion element flanking sequences derived from said insertion element mutant library to use as probe to hybridize to a solid support to which one or more nucleic acids have been fixed as target(s) for hybridisation.

The thus obtained nucleic acid amplification products in above captioned step b) can, for example, be obtained by iPCR using at least one primer or a set of primers based on the sequence of the insertion element or by Transposon Display PCR.

Above-mentioned iPCR is performed by:

- 20 a) digesting the nucleic acid sequences of said insertion element mutant library with a restriction enzyme which optionally recognizes motifs of four nucleotides in the genomic DNA, or with a combination of restriction enzymes resulting in a collection of amplifiable fragments;
- b) self ligation of the genomic fragments thus obtained; and either
- 25 c1) amplification of insertion element flanking sequences using a set of internal primers; or
- c2) amplification of insertion element flanking sequences using a primer or a set of primers based on the terminal part of the insertion element.

The above described amplification products of step c1 can be re-amplified using at least one primer or a set of two nested primers based on the sequence of the insertion element.

5 The above-described amplification products in step b) can also be obtained by so-called transposon display amplification whereby said transposon display amplification is performed by:

- 10 a) digesting the nucleic acid sequences of said insertion element mutant library with a first restriction enzyme that recognizes six conserved nucleotides in the insertion element and with a second restriction enzyme that recognizes a motif of four nucleotides in the genome generating at least one restriction fragment per insertion containing at least the hexacutter site, a part of the insertion element, and part of the insertion element flanking sequence;
- 15 b) ligation of a biotinylated adaptor to the hexacutter sites and a ligation of a second adaptor to the tetracutter sites of the restriction fragments generated in a);
- c) selection of biotinylated restriction fragments using magnetic streptavidin beads;
- 20 d) amplification of insertion element flanking sequences using a primer based on the sequence of the biotinylated adaptor and on the insertion element sequence and a primer complementary to the second adaptor; and
- e) re-amplification of said insertion element flanking sequences using a nested primer based on the insertion element and a primer complementary to the second adaptor.

25 The solid support as described above in any of the methods can be a filter, microarray, microchip containing nucleic acid sequences, or a bead and the like, whereas the nucleic acid sequence is genomic DNA, cDNA, oligonucleotide sequence or PNA.

In the method according to the invention an insertion element mutant library may comprise 30 DNA samples from 100 plants each wherein the insertion element mutant library is built in a 3D array of 10 Block, 10 Row and 10 Column pools, each containing DNA of 100 plants characterized by the three coordinates B, R, C.

Depending on which method according to the current invention is used, *BfaI* or *MseI* and/or *MunI* are used as restriction enzymes.

The organism, having a genome wherein one or more gene insertions according to the invention has to be detected, can in principle be any organism including micro-
5 organisms, such as yeast, *C. elegans*, monocotelydoneous or dicotyledoneous plants, such as preferably maize, but also *Arabidopsis thaliana*, *Petunia*, and other flowering plant species and the like.

A second aspect of the present invention is a composition of elements in the form of
10 a test kit for performing any of the methods described above wherein said kit comprises at least an organized genomic DNA library and, optionally, a restriction enzyme such as *BfaI* capable of recognizing four nucleotides in the genome.

The kit may also be composed of one or more filters carrying an array of amplified products of the flanking sequences derived according to the current invention from a defined
15 organized population of any organism.

So part of the present invention is a kit for performing any of the methods of the invention comprising at least DNA samples of an insertion element mutant library and
15 optionally a set of restriction enzymes and/or primers.

For performing any of the methods of the invention the kit may comprise at least a set of amplified insertion element flanking sequences wherein said set of insertion element flanking sequences optionally have been fixed on a solid support such as a filter, micro-
20 array, microchip containing nucleic acid sequences, or a bead, whereas said set of insertion element flanking sequences are either present in soluble form or dried form.

The set of insertion element flanking sequences can optionally be labeled with for instance fluorescein, however any suitable label known to a person skilled in the art can be
25 used for this purpose.

The system wherein the organized genomic DNA library according to the invention is present, can be, although not limited to, a so-called three dimensional system (3-D array as depicted in FIG. 1A) and is clearly described in Koes et al.,(1995) being herewith incorporated by reference.

Brief Description of the Figures

FIG. 1A depicts a 3-D array showing amplification of pools of dTph1 flanking sequences.

5 FIG. 1B graphically depicts the simple screening for insertion mutants.

FIG. 1C graphically depicts parallel screening for insertion mutants.

FIG. 2 depicts the amplification and detection of transposon flanking sequences using transposon display.

FIG. 3 depicts the generation of a 3D library of flanking sequences.

10 FIG. 4a depicts screening with 4 Kb XbaI Ap2-A fragment as a probe. Transposon display fragments spotted: A-G represent a dilution series as described herein, while Wt is wild-type. The probe was fluorescein-labeled, with an exposure time of 5 min.

15 FIG. 4b depicts parallel screening for Stig 1 insertion mutant. 49 plants (left side) and 100 plants (right side) were pooled and sampled. Two samples (Block III and Row 4) were known to contain an insertion mutant for the Stig 1 gene, whereas one sample (Block I) was known not to contain this insert. Six replicate filters were prepared, harboring spot-blotted DNA from the Ap2A gene (left side of each filter) or the Stig 1 gene (right side). The samples identified did not contain an insertion for the Ap2A gene. PCR products from each sample, obtained by Transposon Display, were fluorescein-labeled and used as a probe.

20 Best Mode of the Invention

The current invention is hereunder described in more detail for sake of clarity to get a better understanding of the invention. In addition, some definitions are hereunder given of what is meant by terms used in the current description.

25 Definitions

-Restriction endonuclease or restriction enzyme: is an enzyme that recognizes a specific nucleotide sequence (target site) in a double-stranded DNA molecule, and will cleave both strands of the DNA molecule at every target site. The cleavage of the DNA molecule can

appear at different positions on the two strands, resulting in the generation of single stranded DNA overhangs, which are specific for the restriction endonuclease.

-Restriction fragments: DNA molecules produced by digestion with a restriction enzyme.

5 Any given genome will be digested by a particular restriction enzyme into a discrete set of restriction fragments.

-Insertion element: refers to any nucleic acid sequence integrated in a genome. Insertion elements comprise, by way of example, but are not limited to, transposable elements, 10 retrotransposons, and T-DNA insertions.

-Insertion element flanking sequences: are the nucleotide sequences flanking a given insertion element in the genome. Insertion flanking sequences can be amplified, by way of non-limiting example, using inverse PCR (iPCR), Transposon Display, Amplification of Insertion Mutagenized Sites (AIMS), vectorette PCR, or thermally asymmetric interlaced PCR (TAIL-PCR).

-Insertion element mutant library: in this invention refers to a set of DNA samples isolated from and representing the population. The DNA pools are organized in a way that allows

20 to refer to the individual or cell line in which an insertion element has inserted in a defined position in the genome, when an insertion is detected in a specific subset of DNA pools of the insertion element mutant library. By way of example, the insertion element mutant library representing a population of 1000 individuals may be obtained by giving each of the 1000 individuals three coordinates (B, R, C) with ($1 \leq B \leq 10$, $1 \leq R \leq 10$, $1 \leq C \leq 10$), and 25 to isolate 30 DNA samples containing the DNA of the 100 individuals, in which each DNA sample is derived from the 100 individuals for which one of the three coordinates equaled a number between 1 and 10.

-Ligation: is the joining of the phosphorylated 5' end of a nucleic acid to a 3' end of a 30 nucleic acid. Ligation of double stranded DNA is mediated by the enzyme DNA ligase and

involves the joining of the 5' and the 3' end of a DNA molecule to the 3' and 5' end a DNA molecule. The 5' end of a nucleic acid can be joined to a 3' end of a second nucleic acid in an intermolecular reaction, or it can be joined to its own 3' end in an intramolecular reaction which will be referred to as back-ligation or self-ligation.

5

-PCR: enzymatic reaction wherein DNA fragments are synthesized from a substrate DNA in vitro as described by Cetus in US Patents 4,683,195 and 4,683,202. Briefly, the reaction involves the use of two synthetic oligonucleotides/primers, which are complementary to nucleotide sequences in DNA molecules which are separated by a short distance of a few hundred to a few thousand base pairs, and the use of a thermostable DNA polymerase. After denaturing double-stranded DNA molecules, the primers will anneal to the complementary nucleotides in the template molecule at a specific annealing temperature. A suitable DNA polymerase then initiates the synthesis of a DNA strand complementary to the template molecule. The chain reaction continues for a variable number of cycles, for instance, a series of 10 to 30 cycles.

10

-DNA amplification: this term is used to denote the in vitro synthesis of double-stranded DNA molecules using, for instance, PCR as nucleic acid sequence amplification technique. The products of the PCR are called amplified DNA fragments.

15

-Primer: this term, in general, refers to a DNA strand which can prime DNA synthesis. DNA polymerase cannot synthesize DNA *de novo* without primers.

20

-An adaptor is a double stranded oligonucleotide that contains a single stranded DNA overhang that can be joined by ligation to a restriction fragment that contains a complementary DNA overhang.

25

-Nucleic acids comprise DNA, RNA, or synthetical analogues thereof. The genome of an organism consists of deoxyribonucleic acid (DNA). DNA is a double helix consisting of a two chains of nucleotides. Each chain consists of a strand of nucleotides linked to each other

30

via phosphodiester bridges between the 5' hydroxyl group of the sugar of one nucleotide linked to the 3' hydroxyl group of the sugar of the adjacent nucleotide. As a consequence, a single stranded DNA molecule has an orientation defined by its 5' and its 3' ends. DNA duplexes contain two single stranded DNA molecules joined together in the opposite orientation. Single stranded DNA consists of a combination of four different nucleotides, containing the bases adenine (A), guanine (G), thymine (T), and cytosine (C). The DNA duplex is a result of the formation of hydrogen bridges between guanine and cytosine and between adenine and thymine residues located on the two different strands. Guanine and cytosine are complementary bases, as are thymine and adenine. The information contained within the genome is transcribed into RNA. RNA is a single stranded chain of ribonucleic acid. RNA consists of four different nucleotides, containing the bases adenine, guanine, cytosine, and uracil (U). Uracil and adenine are complementary bases.

-Hybridization is the process of the binding of a nucleic acid to a second nucleic acid through the formation of hydrogen bridges between the bases of the nucleic acids. Hybridization of nucleic acids is obtained by interaction of two complementary nucleic acids at specific conditions of ionic strength, pH, and temperature.

-Denaturation is the process of separation of two nucleic acid strands. Denaturation can be obtained by increasing the temperature or lowering the ionic strength of a double stranded nucleic acid solution.

-A single stranded nucleic acid is complementary to a second single stranded nucleic acid in case the two strands contain the complementary nucleotides in the opposite order. A nucleic acid can hybridize to a molecule which is its perfect complement, to a nucleic acid which comprises its perfect complement, or to a nucleic acid which is comprised in its perfect complement. Under tolerant hybridization conditions, a nucleic acid can also hybridize to non-perfect complements, provided the non-perfect complement has a sufficient amount of similarity with the perfect complement. Nucleic acids which are not identical but which exhibit a significant amount of similarity are called homologous.

- The term “probe” refers to a single stranded nucleic acid which is capable of binding to a second nucleic acid, which is called the target. Typically, the probe is associated with a label to identify the target to which the probe binds.
- 5 -The term “label” refers to a molecular moiety capable of detection and may include, by way of example, radioactive isotopes, chemiluminescence, fluorescence, dyes, etc. A label can also be a moiety which is capable of interacting with other molecules, which can be detected directly or indirectly, such as, by way of example, but not limited to, antigens which can be detected immunologically by means of antibodies coupled to enzymes which can convert a
- 10 substrate into a detectable molecule.
- 15 -In this invention, the term “probe” comprises the nucleic acid or the pool of nucleic acids which is hybridized to the target, the probe being a nucleic acid or a pool of nucleic acids in solution, and the target being a nucleic acid or a set of nucleic acids fixed to a solid support. “Solid support” refers to conventional supports comprising filters, membranes, silicate supports, such as glass, but also refers to more sophisticated supports like micro-arrays or microchips containing nucleic acid sequences.
- 20 -The term “population” comprises a group of discrete individuals or a group of discrete cell lines, a group containing at least one but typically 1000 individuals or cell lines.

More detailed outline of the technique

To screen for insertion mutants in an efficient way, the plants are not analyzed individually but organized for example in a 3D array of Block, Row, and Column pools of 25 100 plants as described by Koes *et al.* (1995). In a population of 1000 plants, each individual is characterized by 3 coordinates ($B_{1 \leq B \leq 10}$, $R_{1 \leq R \leq 10}$, $C_{1 \leq C \leq 10}$).

Ten Block, ten Row, and ten Column pools of DNA are prepared of 100 plants each generating an insertion element mutant library consisting of 30 DNA samples.

Screening for insertion mutants using iPCR and/or Transposon Display

The insertion element flanking sequences in the different samples of the insertion element mutant library are recovered in four steps. Genomic DNA is digested using a tetracutter restriction enzyme. The obtained fragments are circularized by self-ligation, 5 amplified using a set of internal primers derived from the insertion element, and re-amplified by nested PCR to ensure the specificity of the obtained products (FIG. 1A).

Alternatively, the sequences flanking the insertion elements in a specific pool can be recovered using TRANSPOSON DISPLAY amplification. In this case, the DNA samples 10 of the insertion elements mutant library are digested with a restriction enzyme recognizing a site of 6 bases (this restriction enzyme is referred to as the hexacutter) conserved in the insertion element and a restriction enzyme recognizing a site of 4 bases (this restriction enzyme is referred to as the tetracutter). Adaptors are ligated to the obtained fragments and those fragments containing the hexacutter site are selected. Insertion flanking sequences can be amplified in two steps. In the pre-amplification reaction, a primer based on the hexacutter site adaptor and the insertion element is used in combination with a primer based on the tetracutter site adaptor to amplify a subset of PCR fragments. In the second step, these 15 fragments are used as a template to amplify insertion specific fragments using a transposon specific primer and a primer based on the tetracutter site adaptor (FIG. 2).

To screen for individuals carrying insertions in specific genes of interest, two 20 approaches are possible.

In the first approach, the 30 amplified flanking sequence pools can be displayed on filters and hybridized with one target gene of interest at a time (FIG. 1 B). This method already offers an advantage over the existing gene-specific primer based methods, since the same PCR products can be used to screen many, at least 300-500, genes while upscaling is 25 possible. In the second approach, a large set of targets is displayed on 30 replica filters, and hybridized with the labeled set of 30 amplified sequence pools (FIG. 1 C). This approach becomes useful when more than 30 target genes are being screened for. One great advantage of this method is that *a priori* no sequence information of target genes is needed.

Determining the detection limits

A reconstruction experiment was performed in which *Petunia* W137 genomic DNA was mixed with decreasing amounts of DNA of the heterozygous insertion mutant *PhAp2A* (V2025-6) and subjected to the iPCR protocol. The iPCR products were blotted on mini filters and hybridized to a range of dilutions of an *Ap2A* specific probe. At a probe concentration of 250pg/ml the hybridization signal of the 1/256 *PhAp2A*(V2025-6)/ W137 dilution could clearly be detected above the background signal. Since *Petunia hybrida* W137 individuals harbor around 150-200 *dTph1* elements, this means that a specific transposon flanking sequence was detected against a background of ~ 50000 (256×200) copies. Consequently, specific insertions should be detectable in pools of 100 W137 *Petunia* plants. For other model systems, where less insertions are to be expected per individual, bigger pools could be screened.

Construction of a 3D insertion flanking sequence library and screening for insertion mutants

Thirty genomic DNA samples were prepared of pools of a hundred individuals each, representing a population of 1000 W137 plants. An individual plant carrying the *PhAp2A*(V2025-6) insertion allele was included in the population to serve as a positive control. The flanking sequences of the 30 DNA pools and an insertion mutant dilution series were generated using iPCR with the terminal inverted repeat primers of the transposon, with a set of internal transposon primers or combining the latter iPCR reaction with a nested reamplification with the terminal inverted repeat primers of the transposon (compare Fig.1A). The last approach clearly gave the best amplification on the pools.

For the technique to work, it is essential that all pools have efficiently amplified the flanking sequences of the *dTph1* elements. To control the general quality of the amplification reactions, we checked whether two *dTph1* flanking fragments, *Pete 1* and *Pete2*, had been amplified equally in all pools. *Pete 1* and *Pete2* were identified by Transposon Display (Van den Broeck *et al.*, 1998) and are inherited by all the individuals of the W137 population. This implies that they are present at a 200 fold higher concentration in the pools than a heterozygous insertion present in a single plant of the population. All

pools were found positive for *Pete I* and *Pete2*, except R9 in the first series and R5 in the second series.

However, the flanking sequences of *dTph1* in *Cep2* in plant (VIII, 6, h) of this population, previously identified by the classical 3D screening approach, did only show up as a positive in one of the three dimensions. Therefore, a more sensitive positive control was developed by adding a 1/100 dilution of genomic DNA of a plant heterozygous for the *PhAp2A*(V2025-6) insertion allele to all of the pools of genomic DNA. After digestion and nested iPCR, the pool products were spot blotted and hybridized with a *PhAp2A* specific probe. The protocol was repeated until all pools proved positive for the *PhAp2A* insertion. After this qualitative improvement, the *Cep2* insertion could be detected in the pools that we expected to be positive (FIG. 3A and 3B).

Parallel screening for insertion mutants

For parallel screening, the transposon flanking sequence pools were labeled and used as a probe to hybridize potentially tagged genes. A dilution series of *PhAp2A* and negative control target DNA (vector sequence) was spotted on small round filters and hybridized with a labeled Block III pool to determine the amount of DNA that needed to be displayed on the target filters to obtain a clear positive signal. A set of 30 replicas, each displaying 80 target genes, was made using a Beckman Biomek 2000 Laboratory Automated Workstation. Most of the displayed targets (73) were PCR amplified inserts from random picked cDNA clones from a carpel specific cDNA library. Among the seven targets with known sequences was *PhAp2A*, which was included as a constitutive positive control for the 30 samples. Using the classical 3D screening method, a *dTph1* insertion had been identified in *PhAp2C* in plant (V, 8, g), thus *PhAp2C* was used as a positive control representing a single insertion mutant appearing in the population.

The 30 pools of transposon flanking sequences obtained by nested iPCR were fluorescein labeled and hybridized to the 30 target gene replicas. Each target was displayed three times and formed a pattern which can be easily distinguished from spurious spots on the filter. The control *PhAp2A* signal can be detected as a three dot diagonal at position (2, E) on each filter using probes made of the insertion element flanking sequences which had

been amplified nicely as determined by the quality control assay described under construction of a 3D insertion flanking sequence library. A *dTph1* insertion in *PhAp2C* was detected in the correct position at the diagonal of position (4, E) of the filters hybridized with the probes made of the insertion element flanking sequences which passed the quality control assay, and which were derived from the insertion element mutant library samples which contained the DNA of the individual plant that contained a *dTph1* insertion in *PhAp2C*.

Examples

Method for determination of detection limits

Genomic DNA of the heterozygous *PhAp2A* insertion mutant was diluted with increasing amounts of wild type DNA (ranging from 1/1 to 1/256 insertion mutant/wild type DNA). 10 μ g of each DNA mix was digested in 100 μ l 1x New England Biolabs buffer 4 with the tetracutter enzyme *Bfa*I, which does not cut within the 284bp *dTph1* element. After complete digestion, the enzyme was heat inactivated and the mixture was phenol:chloroform extracted, precipitated and dissolved in dd H₂O. 2 μ g of DNA was ligated ON at 14° C in 400 μ l 1xT4 ligation buffer in the presence of 2.5 units of T4 DNA ligase. The ligation mixture was extracted with phenol:chloroform, with chloroform and precipitated in the presence of 20 μ g of calf thymus tRNA, washed and dried. The vacuum dried pellet was re-suspended in 30 μ l of dd H₂O. 5 μ l of the self-ligated fragments were used in the iPCR reaction with the outward transposon inverted repeat primer (TIR), consisting of 35 cycles of 1 min denaturation at 95° C, 1 min annealing at 55° C, and 1.5 min polymerisation at 72° C. The PCR reactions were also performed on equivalent amounts of undigested W137 and insertion mutant DNA. The reaction products were spotted in 8-plicate on individual Hybond N⁺ filters that had been cut small enough to fit into 96 well plates, denatured, neutralized and baked as prescribed by the manufacturer. The filters were pre-hybridized in 50 μ l of hybridization mix (as prescribed by Amersham). 50 ng of a 900bp *Spe*I/*Eco*RI *Ap2A* fragment was ³²P labeled with a Megaprime kit in a 50 μ l reaction with 5 μ l α -dCTP (incorporation ~ 50%). Half of the denatured probe was diluted to 1200 μ l with hybridization mix, 600 μ l was divided in 12 aliquots of 50 μ l, that were added to the pre-hybridization mix, 600 μ l was used for seven consecutive two-fold dilutions. Thus, the

concentration of the probe in the first series of 12 hybridizations was ~ 1 ng/100 μ l, decreasing each time by a factor of two for the next seven dilutions. Washes were performed at 60° C., 2x in 2xSSC, 0.1%SDS and 4x in 0.5xSSC, 0.1%SDS for 10 min each. Hybridized filters were exposed to a Phosphor Image cassette and scanned using a Beckman
5 Phosphor Imager.

Method for the construction of a 3D insertion flanking sequence library including quality control

1000 W137 plants were organized in a 3D array of 10 blocks, 10 rows, and 10 columns, as described by Koes et al. (1995). DNA was extracted from the leaves of the 30 pools using a CTAB extraction method. DNA extracted from a heterozygous *Ap2A* insertion mutant was added to each pool at a ratio of 1:100 as a positive control. 10 μ g of each of the 30 DNA samples was digested at 37° C for 6h by 10 units of Biolabs *Bfa*I restriction enzyme in 1x NEB4 buffer. The restriction reactions were extracted with phenol, phenol:chloroform, and chloroform. 1 μ l of 10 mg/ml tRNA was added, the samples were precipitated with NaOAc and EtOH, washed with 70% EtOH and dissolved in 100 μ l H₂O. 20 μ l of this mix (2 μ g) was ligated overnight at 16° C by 6 units of T4 DNA ligase (Pharmacia) in 400 μ l of ligation buffer (10mM MgCl₂, 30mM Tris.Cl pH7.8, 10mM DTT, 0.5mM ATP). The ligation mixture was extracted with phenol, phenol:chloroform, and chloroform, precipitated as above, and dissolved in 30 μ l H₂O. 5 μ l of this solution was used as template in a first amplification reaction performed with two internal transposon specific primers (IntA: 5'-GGGAATTCTTGAACGAGTTGCCTC-3' (SEQ.I.D.NO. 1) and IntB: 5'-GGGAATTCAGTGAAATTGCGC-3' (SEQ.I.D. NO. 2), see also Souer *et al.*, 1995), for 35 cycles of 30s at 94° C, 30s at 55° C and 1 min. 30 s at 72° C in 50 μ l 1x Perkin
15 Elmer with 30 pmol of each primer, 200nM dNTPs, 4mM MgCl₂ and 1 unit Perkin Elmer Taq polymerase. 3 μ l of the resulting transposon flanking sequences were re-amplified with a primer based on the terminal inverted repeat of the transposon (5'-GGGAATTCGCTCCGCCCTG-3') (SEQ.I.D. NO. 3).

Quality control of the amplified flanking sequence pools

0.25 μ l of the PCR products were spot blotted on a Hybond N⁺ membrane and hybridized with an α -³²P dCTP *Ap2A* specific probe to see whether the control insertion mutant could be detected. Washes and detection were as in the reconstruction experiment.

5

Method for the parallel screening of insertion mutants

20 μ l aliquots of target DNA solution (100 ng/ μ l) were distributed in V bottom shaped microtiter plates and spotted on Hybond N⁺ filters using a Beckman Biomek 2000 Laboratory Automation Workstation. Each replica had the size of 1/3 96 well microtiterplate. On each of the 4 \times 8 positions (from 1 to 4 and from A to H), a matrix of 10 3 targets was displayed as follows:

a b c
a c b
c a b

15

In this way, 4 \times 8 \times 3 = 96 targets can be displayed per replica (we have used a 4 \times 7 \times 3 = 84 target array). The filters were treated for hybridization as described by Amersham. 5-10 μ l of the amplified flanking sequence pools were labeled with fluorescein using the Gene Images random prime labeling module (Amersham). A small amount of IR primer was added in the labeling reaction to ensure that small fragments would be labeled. The replica filters were hybridized in 5m1 hybridization buffer and washed according to the Amersham protocol. The hybridizing signals were visualized using the Gene Images Detection Module (Amersham) after exposure to Fuji X-RAY films.

20

SCREENING FOR INSERTION MUTANTS USING TRANSPOSON DISPLAY

Determining the detection limits

A reconstruction experiment was performed in which Petunia W137 genomic DNA was mixed with decreasing amounts of DNA of an insertion mutant containing a *dTphI* insertion in *Ap2A* (A=1/2, B=1/4, C= 1/8, D=1/16, E=1/32, F=1/64, G=1/128), and subjected 30 to the transposon display amplification protocol, which was performed with unlabeled PCR

primers. The Transposon Display amplification products were spot blotted on filters and hybridized with a labeled *Ap2A* specific probe. The amplified *dTph1* flanking fragment containing part of the *Ap2A* gene could readily be detected in the 1/128 dilution of the mutant DNA with the wild type W137 DNA (FIG. 4A).

5

Construction of a 3D library of insertion flanking sequences and screening for insertion mutants.

A second reconstruction experiment was performed in which the genomic DNA of a pool of respectively 4 (2×2), 9 (3×3), 16 (4×4), 25 (5×5), 36 (6×6), 49 (7×7), 64 (8×8), 81 (9×9) and 100 (10×10) different individuals, was isolated. In each pool, 1 of the individuals was subsequently replaced by an individual containing a *dTph1* insertion in the *Ap2A* gene and DNA's were extracted.

Transposon Display amplification was performed on each of the pools using unlabelled primers and the resulting Transposon Display amplification products were spot blotted on filters and hybridized with an *Ap2A* specific probe. The amplified *dTph1* flanking fragment containing part of the *Ap2A* gene could readily be detected as a positive signal in each of the pools harboring the *Ap2A* insertion. In control pools not containing DNA from the insertion mutant, no such signal was observed. The *dTph1* flanking sequences could then be amplified from all 30 pools of a population of 1000 organized in Block, Rows and Columns, spotted on a filter and used to screen for insertions in any gene of interest.

Parallel screening for insertion mutants

In order to screen for insertions in many genes simultaneously, the amplified Transposon Display fragments are labeled and used as a probe to hybridize a filter containing a set of target genes.

Both Transposon Display fragments obtained from the amplification of *dTph1* flanking fragments from the dilution series F and G, described above, and those obtained from the 2×2 , 6×6 , 8×8 and 10×10 pools containing an individual with a *dTph1* insertion in *Ap2A*, mentioned above, were separately labeled and used to hybridize filters displaying

a fragment of the Ap2A gene. All probes obtained by Transposon Display PCR on the pools containing the Ap2A insertion, were able to detect the *Ap2A* gene on the filters.

The *dTph1* flanking sequences can be amplified from all 30 pools of a population of 1000 organized in Block, Row and Columns, labeled, and used as probes to hybridize filters containing multiple gene targets. An insertion in gene *Stig1*, was identified in the correct pools of Transposon Display fragments obtained from such a population (FIG. 5B).

METHODS TO SCREEN FOR INSERTION MUTANTS USING TRANSPOSON DISPLAY

Transposon Display was performed as described by Van den Broeck *et al.*, 1998, with the following modifications:

The streptavidin beads were suspended in 50 instead of 200 μ l T01E buffer, the selective pre-amplification reactions were performed with 5 μ l of the above 50 μ l in a reaction volume of 50 μ l using the *MunI*-ACAC primer and an *MseI* primer, using however a touch down PCR profile as described in the hot PCR. The pre-amplification products were diluted 10 times and re-amplified using 5 μ l of the diluted pre-amplification product, the IR primer and the *MseI* primer, in a reaction volume of 50 μ l but without labeling the IR primer, resulting in the final product.

To perform simple screening for insertion mutants, the 50 μ l of final product was dried, re-suspended in 5 μ l water, denatured and spotted on Hybond N+, and hybridized with a denatured gene specific probe labeled using the CDP-star kit of Amersham, in a buffer containing 5xSSC, 60° C, and blots were washed at 60° C at a stringency of 0.5x SSC.

To perform parallel screening for insertion mutants, 2 μ l of the 50 μ l of the final product was labeled using a linear PCR using 1,5 μ l IR primer, 10 μ l nucleotide mix of the CDP-star kit of Amersham, 5 μ l 10xPCR buffer and 0,2 μ l Taq polymerase in a volume of 50 μ l, using a PCR profile of 30 cycles of 94° C/30s, 56° C/30s, 72° C/60s.

Hybridizations of filters with target genes were performed with these probes in a buffer containing 5xSSC at 60° C, and blots were washed at 60° C at a stringency of 0.5xSSC.

References

- Ballinger, D.G., and Benzer, S. (1989). Targeted gene mutations in *Drosophila*. PNAS **86**, 9402-9406.
- Bechtold N. , Ellis, J., Pelletier, G. (1993). In planta Agrobacterium mediated gene transfer by infiltration of adult *Arabidopsis thaliana* plants. C.12. Acad. Sci. Paris, Sciences de la vie/Life Sciences **316**, 1194-1199.
- Burns, N., Grimwade, B., Ross-Macdonald, P.B., Choi, E-Y., Finberg, K., Roeder, G.S. and Snyder, M. (1994). Large-scale analysis of gene expression, protein localization, and gene disruption in *Saccharomyces cerevisiae*. Genes and Dev. **8**, 1087-1105.
- Das, L. and Martienssen, R. (1995). Site-Selected Transposon Mutagenesis at the hcf106 Locus in Maize. Plant Cell **7**(3), 287-294.
- Gerats, A.G.M., BeId, M., Huits, H., Prescott, A. (1989). Gene tagging in *Petunia hybrida* using homologous and heterologous transposable elements. Dev.Gen. **10**, 561-568.
- Kaiser, K., and Goodwin, S.F. (1990). "Site-selected" mutagenesis of *Drosophila*. PNAS **87**, 1686-1690.
- Koes, R., Souer, E., Van Houwelingen, A., Mur, L., Spelt, C., Quattrocchio, F., Wing, J., Oppedijk, B., Ahmed, S., Maes, T., Gerats, T., Hoogeveen, P., Meesters, M., Kloos, D., Mol, J.N.M. (1995). Targeted gene inactivation in petunia by PCR-based selection of transposon insertion mutants. PNAS **92**(18), 8149-8153.
- McKinney, E.G., Aali, N., Traut, A., Feldmann, K.A., Belostotsky, D.A., McDowell, J.M., Meagher, R. (1995). Sequence-based identification of T-DNA insertion mutations in *Arabidopsis*: Actin mutants *act2-1* and *act4-1* Plant Journal **8**(4), 613-622.
- Mollier, P., Montoro, P., Delarue, M., Bechtold, N., Bellini,C., Pelletier, G. (1995). Promoterless gusA expression in a large number of *Arabidopsis thaliana* transformants obtained by the in planta infiltration method. C.R.Acad.Sci. Paris, Sciences de la vie/Life sciences **318**, 465-474.
- Riley, J., Butler, R., Ogilvie, D., Finniear, R., Jenner, R., Powell, S., Anand, S., Smith, S., and Markham, A.F. (1990). A novel, rapid method for the isolation of terminal sequences from yeast artificial chromosome (YAC) clones. NAR **18**, 2887-2890.

- Schena, M., Shalon, D., Davis, R.W. and Brown, P.O. (1995). Quantative monitoring og gene expression patterns with a complementary DNA microarray. *Science* **270**, 467-470.
- 5 Shoemaker, D.D., Lashkari, D.A., Morris, D., Mittmann, M. and Davis, R.W. (1996). Quantitative phenotypic analysis of yeast deletion mutants using a highly parallel molecular bar-coding strategy. *Nature Genetics* **14**, 450456.
- 10 Smith, V., Botstein, D. and Brown, P.O. (1995). Genetic footprinting: A genomic strategy for determining a gene's function given its sequence. *PNAS* **92**, 6479-6483.
- 15 Souer, E., Quattrochio, F., de Vetten, N., Mol, J. and Koes, R. (1995). A general method to isolate genes tagged by a high copy number transposable element. *Plant Journal* **7**(4): 677-685.
- 15 Van den Broeck, D., Maes, T., Sauer, M., Zethof, J., Van Montagu, M. and Gerats, T. (1998). Transposon Display identifies individual transposable elements in high copynumber lines. *Plant Journal* **13**(1):1 21-129.
- 20 Zwaal, R.R., Broecks, A., Van Meurs, J., Groenen, J.T.M., Plasterk, R.H.A. (1993). Target-selected gene inactivation in *Caenorhabditis elegans* by using a frozen transposon insertion mutant bank. *PNAS* **90**(16): 7431-7435.

SEQUENCE LISTING

<110> Vlaams Interuniversitair Instituut voor Biotechnol

5 <120> Method of parallel screening for insertion mutants and
a kit to perform this method.

<130> V2/002-V012

10 <140> PCT/EP98/07551

<141> 1998-11-23

<150> EP 97203680.0

<151> 1997-11-25

15 <160> 3

<170> PatentIn Ver. 2.1

20 <210> 1

<211> 25

<212> DNA

<213> Artificial Sequence

25 <220>

<223> Description of Artificial Sequence: internal
transposon specific primer

<220>

30 <221> primer_bind

<222> (1)..(25)

<400> 1

ggaaattctt gaacgagttg tcctc

25

35

<210> 2

<211> 24

<212> DNA

<213> Artificial Sequence

```
<220>
<223> Description of Artificial Sequence:internal
      transposon specific primer

5   <220>
    <221> primer_bind
    <222> (1)..(24)

          <400> 2
10  gggaaattcag tgtaaatttt gcgc                         24

          <210> 3
          <211> 20
          <212> DNA
15  <213> Artificial Sequence

          <220>
          <223> Description of Artificial Sequence:primer based on
                  the terminal repeat of the transposon

20
          <220>
          <221> primer_bind
          <222> (1)..(20)

25  <400> 3
    gggaaattcgc tccgccccctg                           20

30
```

CLAIMS

What is claimed is:

1. Method of simultaneous screening for one or more gene insertion mutants in a population of any organism or cell line derived thereof by:

5 a) preparing an insertion element mutant library originating from a defined population of an organism or cell line wherein said insertion(s) have to be detected,

 b) amplifying the insertion element flanking sequences from said insertion element mutant library,

10 c1) either fixing the set of thus obtained nucleic acid amplification products representing said insertion element flanking sequences derived from said insertion element mutant library to a solid support as target for hybridization, or

15 c2) producing a set of labelled amplification products representing said insertion element flanking sequences derived from said insertion element mutant library to use as probe to hybridize to a solid support to which one or more nucleic acids have been fixed as target(s) for hybridisation.

20 2. Method according to claim 1 wherein the thus obtained nucleic acid amplification products in step b) are obtained by iPCR using at least one primer or a set of primers based on the sequence of the insertion element.

25 3. Method according to claim 2 wherein the iPCR is performed by

 a) digesting the nucleic acid sequences of said insertion element mutant library with a restriction enzyme which optionally recognizes motifs of four nucleotides in the genomic DNA, or with a combination of restriction enzymes resulting in a collection of amplifiable fragments,

 b) self ligation of the genomic fragments thus obtained and either

 c1) amplification of insertion element flanking sequences using a set of internal primers or

 c2) amplification of insertion element flanking sequences using a (set of) primers based on the terminal part of the insertion element.

4. Method according to claim 3 wherein the amplification products of step c1
are re-amplified using at least one primer or a set of two nested primers based on the
sequence of the insertion element.

5 5. Method according to claim 1 wherein the amplification products in step b)
are obtained by transposon display amplification.

6. Method according to claim 5 wherein transposon display amplification is
performed by

10 a) digesting the nucleic acid sequences of said insertion element mutant
library with a first restriction enzyme that recognizes six conserved nucleotides in the
insertion element and with a second restriction enzyme that recognizes a motif of four
nucleotides in the genome generating at least one restriction fragment per insertion
containing at least the hexacutter site, a part of the insertion element, and part of the insertion
element flanking sequence,

15 b) ligation of a biotinylated adaptor to the hexacutter sites and a ligation
of a second adaptor to the tetracutter sites of the restriction fragments generated in a),

c) selection of biotinylated restriction fragments using magnetic
streptavidin beads,

20 d) amplification of insertion element flanking sequences using a primer
based on the sequence of the biotinylated adaptor and on the insertion element sequence and
a primer complementary to the second adaptor,

25 e) re-amplification of said insertion element flanking sequences using
a nested primer based on the insertion element and a primer complementary to the second
adaptor.

7. Method according to any of the preceding claims wherein the solid support
is a filter, micro-array or chip containing nucleic acid sequences.

8. Method according to any of the preceding claims wherein the nucleic acid sequence is genomic DNA or cDNA.

9. Method according to any of the preceding claims wherein the insertion element mutant library comprises of 30 DNA samples from 100 plants each.

10. Method according to claim 9 wherein the insertion element mutant library is built in a 3D array of 10 Block, 10 Row and 10 Column pool each containing DNA of 100 plants characterised by the three coordinates B, R, C.

11. Method according to any of the claims 1-4 wherein BfaI is used as restriction enzyme.

12. Method according to the claims 5 or 6 wherein MseI and/or MunI are used as restriction enzyme.

13. Kit for performing any of the methods of claim 1-12 comprising at least DNA samples of an insertion element mutant library and optionally a set of restriction enzymes and/or primers.

14. Kit for performing any of the methods of claim 1-12 comprising at least a set of amplified insertion element flanking sequences.

15. Kit according to claim 14 wherein the set of insertion element flanking sequences have been fixed on a solid support such as a filter, micro-array or microchip containing nucleic acid sequences.


16. Kit according to claims 14 or 15 wherein the set of insertion element flanking sequences is either present in soluble form or dried form.

17. Kit according to claim 16 wherein the set of insertion element flanking sequences are labelled with for instance fluorescein.

Abstract

The current invention is a novel approach termed “parallel screening” which allows simultaneously screening of a population for insertions in all genes cloned from that or a closely related organism. In order to test this approach, the flowering plant *Petunia hybrida* was used as a model system. *Petunia hybrida* line W137 contains a high copy number of the endogenous transposable element *dTph1* and has been previously presented as a genetic tool. A 3D library of the plant genomic DNA of 1000 *Petunia hybrida* W137 plants was generated. The 3D library consists of 30 pools of DNA from 100 plants each. These were used to generate 30 pools of insertion flanking sequences by nested iPCR using a set of transposon specific primers or by Transposon Display PCR. Insertions into a gene were detected by hybridizing the amplified insertion flanking sequences fixed to a filter with a gene specific probe, an approach termed simple screening for insertion elements. Alternatively, the amplified insertion element flanking sequences were labeled and used as a probe to hybridize a filter displaying multiple gene targets, an approach termed parallel screening for insertion elements, which allows the simultaneous screening for insertions in all genes of an organism, appearing in a population of insertion mutants.

A: Amplification of pools of *dTph1* Flanking sequences



Harvesting of the 30 DNA pools of the 3D library




Figure 1A

B: Simple screening for insertion mutants




Figure 1B

C: Parallel screening for insertion mutants




Figure 1c

Figure 1: Parallel screening for insertion mutants using iPCR: Schematic outline of the technique

A: Amplification of the *dTph1* flanking sequences: 1000 plants are organized in a 3D array, and 30 genomic DNA pools are prepared, each representing 100 individual plants. The 30 pools of genomic DNA are digested with a tetracutter enzyme (*Bfa*I). The genomic fragments are self-ligated and the insertion flanking sequences are amplified by PCR using two internal insertion specific primers, IntA and IntB. The specificity of the amplified products can be increased by nested reamplification of the flanking sequences using the terminal inverted repeat primer (TIR).

B: Simple screening for insertion mutants: The amplified flanking sequence pools are displayed on a filter and hybridized with a probe for any target gene of interest in a serial manner.

C: Parallel screening for insertion mutants: The 30 amplified flanking sequence pools are labelled and used to probe an array of target genes displayed on 30 replica filters (or microarrays) in a set of 30 hybridization reactions

**AMPLIFICATION and DETECTION of TRANSPOSON FLANKING SEQUENCES
USING TRANSPOSON DISPLAY (After Van den Broeck *et al.*, 1998)**




FIGURE 2

4/6





Figure 3: Generation of a 3D library of flanking sequences

DNA of an *PhAp2A* insertion mutant was added as a positive control to all the 3D pools, *dTph1* flanking sequences were amplified as described. Pools VII, 6, h were spot blotted and hybridized with A: a *PhAp2A* probe; B: a *Cep 2* probe.

5/6



Dilution: Mut A B C D E F G Wt

Figure 4a: 3D Screening with a 4Kb XbaI *Ap2A* fragment as a probe. Transposon display fragments spotted; A-G represent a dilution series as described in the text; Wt is wildtype. The probe was fluorescein-labeled, exposure time 5 minutes.

6/6




Figure 4b: Parallel screening for *Stig 1* mutant

49 plants (left side of the picture) or 100 plants (right side) were pooled and sampled. Two samples (Block III and Row 4) were known to contain an insertion mutant for the *Stig 1* gene, whereas one sample (Block I) was known not to contain this insert. Six replicate filters were prepared, harboring spotblotted DNA from the *Ap2A* gene (left side of each filter) or the *Stig 1* gene (right side).

The samples mentioned did not contain an insertion for the *Ap2A* gene. PCR products from each sample, obtained by Transposon Display, were fluorescein-labeled and used as a probe. Exposure time 5 minutes.